Please login to the form below

Not currently logged in
Email:
Password:

Biocon in drug development talks with Bayer

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

According to a report in the Indian newspaper, The Economic Times, biotechnology company, Biocon, is in discussions with German pharmaceutical company Bayer regarding the co-development of biotechnology drugs.

Biocon's managing director and chairman, Kiran Mazumdar-Shaw, told the newspaper that the agreement, which initially involved research activities, could also include biotech drug development activities.

Biocon, which has not commented on the report, derives much of its revenue from ethical drugs, such as head and neck cancer treatment, BioMab EGFR, as well as its enzyme business. The firm's strategy is to increase the share of research services business to a quarter of its total revenue in the next five years from about 15 per cent currently.

Bristol-Myers Squibb (BMS) revealed back in March 2007 that it was to partner with Biocon's research services unit, Sungene, and set up a facility in Bangalore to aid discovery and early drug development.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics